Modified VR-CAP and Acalabrutinib As Induction Therapy for Transplant-Eligible Patients with Mantle Cell Lymphoma

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma »